<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078374</url>
  </required_header>
  <id_info>
    <org_study_id>Version 2.0</org_study_id>
    <nct_id>NCT03078374</nct_id>
  </id_info>
  <brief_title>MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)</brief_title>
  <official_title>A Safety and Feasibility Study of Low-intensity Anticoagulation With HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Clinical and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain single-center safety and feasibility data on patients
      managed with reduced anti-coagulation, and the incidence of thrombotic and bleeding adverse
      events associated with the HeartMate 3 LVAS therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with implanted HeartMate 3 device will be bridged with heparin until target
      International Normalized Ratio (INR) of 2,0 - 3,0 will be reached on anticoagulation therapy
      with Warfarin. Along with Warfarin, Acetylsalicylic Acid (ASA) will be administered in dose
      of 100mg per day. Enrollment for the study will take place in 1-6 weeks post implant of
      HeartMate 3. Low-intensity anticoagulation protocol will be started at 6 weeks after implant.
      Target INR of 1,5-1,9 will be maintained and ASA will be administered in dose of 100mg per
      day with adjustments based on VerifyNow testing. Follow up will last for 12 months after
      HeartMate 3 implantation. Subsequently, the objectives of the study will be analyzed and
      evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 11, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival-free rate of thromboembolic and hemorrhagic events</measure>
    <time_frame>12 months</time_frame>
    <description>12 month survival-free rate of thromboembolic events (i.e. pump thrombosis, disabling stroke MRS&gt;3) and hemorrhagic events (major bleeding, hemorrhagic stroke).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse Event rates as assessed per INTERMACS definitions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Reduced Anticoagulation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Reduced anticoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Reduced dosage to obtain lower INR range</description>
    <arm_group_label>Reduced Anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients implanted with HeartMate 3 LVAS irrespective of an indication

          -  data collection for major thrombophilic mutations including anti-phospholipid syndrome
             and lupus anticoagulant testing prior to low-intensity protocol anticoagulation
             initiation has been performed

          -  patient will be compliant with an anticoagulation management in a judgment of the
             investigator

          -  patient in stable condition with anticipated home discharge

        Exclusion Criteria:

          -  absence of an informed consent

          -  presence of additional MCS e.g. ECMO, RVAD in less than 7 days prior to low- intensity
             protocol anticoagulation initiation

          -  known history of major thrombotic event e.g. DVT

          -  presence of other than biological valve prosthesis in aortic position

          -  left atrial appendage in patients with atrial fibrillation or flutter not addressed by
             resection or exclusion at a time of the implant

          -  hemodynamically significant or symptomatic carotid artery stenosis prior to
             low-intensity protocol anticoagulation initiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Netuka, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Clinical and Experimental Medicine</affiliation>
  </overall_official>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0735109715068394</url>
    <description>Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study.</description>
  </link>
  <link>
    <url>http://www.nejm.org/doi/full/10.1056/NEJMoa1610426</url>
    <description>A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure.</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S1053249816301449</url>
    <description>Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure.</description>
  </link>
  <reference>
    <citation>Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, Rao V, Morshuis M, Marasco S, Beyersdorf F, Damme L, Schmitto JD. Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study. J Am Coll Cardiol. 2015 Dec 15;66(23):2579-2589. doi: 10.1016/j.jacc.2015.09.083.</citation>
    <PMID>26670056</PMID>
  </reference>
  <reference>
    <citation>Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, Walsh MN, Milano CA, Patel CB, Jorde UP, Pagani FD, Aaronson KD, Dean DA, McCants K, Itoh A, Ewald GA, Horstmanshof D, Long JW, Salerno C; MOMENTUM 3 Investigators. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med. 2017 Feb 2;376(5):440-450. doi: 10.1056/NEJMoa1610426. Epub 2016 Nov 16.</citation>
    <PMID>27959709</PMID>
  </reference>
  <reference>
    <citation>Netuka I, Kvasnička T, Kvasnička J, Hrachovinová I, Ivák P, Mareček F, Bílková J, Malíková I, Jančová M, Malý J, Sood P, Sundareswaran KS, Connors JM, Mehra MR. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. J Heart Lung Transplant. 2016 Jul;35(7):860-7. doi: 10.1016/j.healun.2016.05.019. Epub 2016 May 31.</citation>
    <PMID>27435529</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Clinical and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Ivan Netuka, MD, Ph.D., Assoc. Prof. of Cardiac Surgery</investigator_full_name>
    <investigator_title>Vice Chairman of Cardiac Centre</investigator_title>
  </responsible_party>
  <keyword>Reduced anti-coagulation, mechanical circulatory support.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

